On November 3, 2017 Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, reported that new data will be presented in an oral presentation and a trial in progress poster at the upcoming CTOS meeting that will be held November 8-11 at the Grand Wailea Resort in Hawaii (Press release, Adaptimmune, NOV 3, 2017, View Source [SID1234521554]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Sandra P. D’Angelo of Memorial Sloan Kettering Cancer Center will be presenting an update on the company’s ongoing study of NY-ESO SPEAR T-cells in synovial Sarcoma. There will also be a trial in progress poster for the ongoing study of NY-ESO SPEAR T-cells in Myxoid/Round Cell Liposarcoma (MRCLS). Details are below:

Oral Presentation:

Title: Open Label Non-Randomized Multi-Cohort Pilot Study of Genetically Engineered NY-ESO-1 SPEAR T-Cells in HLA-A2+ Patients with Synovial Sarcoma (NCT01343043)
– Abstract ID: 2804696
– Session Title: Symposium 1: Medical, Pediatric and Young Adult Oncology
– Session Time: November 9, 2017 from 10:30 AM to 12:00 PM
– Location: Haleakala 1
Trial in Progress Poster:

Title: A Pilot Study of NY-ESO-1 SPEAR T-Cells in Subjects with Advanced Myxoid/Round Cell Liposarcoma (NCT02992743)
– Abstract ID: 2804696
– Presentation time: The poster will be on display throughout the meeting.
– Poster Session: November 9, 2017 from 5:30 PM to 6:30 PM
– Location: Haleakala 2 & 3